Global Osteoarthritis Gene Therapy Market

Osteoarthritis Gene Therapy Comprehensive Study by Type (Synovium Injection, Cartilage Injection), Vectors (Non-viral, Retrovirus, Lentivirus, Adenovirus, Adeno-associated virus (AAV), HSV), End User (Hospitals and clinics, Orthopedic Centers, Assisted living Facilities, Nursing Homes, Ambulatory Surgical Centers, Others) Players and Region - Global Market Outlook to 2028

Osteoarthritis Gene Therapy Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Osteoarthritis Gene Therapy Market Scope
Osteoarthritis most common form of arthritis that occurs when flexible tissue at the ends of bones wears down. Osteoarthritis disorder most commonly affects joints in the hands, knees, hips, and spine. Gene therapy is a treatment that uses genes to treat or prevent disease. Osteoarthritis Gene Therapy treatment transfers a potentially therapeutic gene safely to human arthritic joints to obtain intra-articular expression of a biologically active transgene product.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledFlexion Therapeutics Inc. (United States), GeneQuine Biotherapeutics (Germany), Novartis AG (Switzerland), Smith & Nephew (United Kingdom), Genascence (United States), Kolon TissueGene, Inc. (United States), Sanofi (France), Parexel International Corporation (United States), Medipost (South Korea) and Mundipharma(Germany)
CAGR%


The market is fragmented by numerous key players who have a bargaining power high in the global osteoarthritis therapeutics market as the market is dominated by several key players. The intensity of rivalry appears to be high in this market as competitors are numerous and the drugs are undifferentiated. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Osteoarthritis Gene Therapy market throughout the predicted period.

Flexion Therapeutics Inc. (United States), GeneQuine Biotherapeutics (Germany), Novartis AG (Switzerland), Smith & Nephew (United Kingdom), Genascence (United States), Kolon TissueGene, Inc. (United States), Sanofi (France), Parexel International Corporation (United States), Medipost (South Korea) and Mundipharma(Germany) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Osteoarthritis Gene Therapy market by Type and Region with country level break-up.

On the basis of geography, the market of Osteoarthritis Gene Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
In November 2018, Mundipharma signed a multi-year agreement with Kolon Life Sciences, where they secured exclusive rights for Invossa osteoarthritis therapy in Japan.



Influencing Trend:
Increase in the Prevalence of arthritis

Market Growth Drivers:
Growing Occurrence of Orthopedic Disorders and Increase Awareness of Gene Therapy

Challenges:
Rising Adoption of Non-Drug Pain Management Therapies

Restraints:
High-Cost Associated with Therapy

Opportunities:
Presence of a large number of Osteoarthritis Susceptible patients

Key Target Audience
Government Regulatory, Research Organizations, Hospitals and Clinics and Orthopedic Centers

Report Objectives / Segmentation Covered

By Type
  • Synovium Injection
  • Cartilage Injection
By Vectors
  • Non-viral
  • Retrovirus
  • Lentivirus
  • Adenovirus
  • Adeno-associated virus (AAV)
  • HSV

By End User
  • Hospitals and clinics
  • Orthopedic Centers
  • Assisted living Facilities
  • Nursing Homes
  • Ambulatory Surgical Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Occurrence of Orthopedic Disorders
      • 3.2.2. Increase Awareness of Gene Therapy
    • 3.3. Market Challenges
      • 3.3.1. Rising Adoption of Non-Drug Pain Management Therapies
    • 3.4. Market Trends
      • 3.4.1. Increase in the Prevalence of arthritis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Osteoarthritis Gene Therapy, by Type, Vectors, End User and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Osteoarthritis Gene Therapy (Value)
      • 5.2.1. Global Osteoarthritis Gene Therapy by: Type (Value)
        • 5.2.1.1. Synovium Injection
        • 5.2.1.2. Cartilage Injection
      • 5.2.2. Global Osteoarthritis Gene Therapy by: Vectors (Value)
        • 5.2.2.1. Non-viral
        • 5.2.2.2. Retrovirus
        • 5.2.2.3. Lentivirus
        • 5.2.2.4. Adenovirus
        • 5.2.2.5. Adeno-associated virus (AAV)
        • 5.2.2.6. HSV
      • 5.2.3. Global Osteoarthritis Gene Therapy by: End User (Value)
        • 5.2.3.1. Hospitals and clinics
        • 5.2.3.2. Orthopedic Centers
        • 5.2.3.3. Assisted living Facilities
        • 5.2.3.4. Nursing Homes
        • 5.2.3.5. Ambulatory Surgical Centers
        • 5.2.3.6. Others
      • 5.2.4. Global Osteoarthritis Gene Therapy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Osteoarthritis Gene Therapy (Price)
      • 5.3.1. Global Osteoarthritis Gene Therapy by: Type (Price)
  • 6. Osteoarthritis Gene Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Flexion Therapeutics Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GeneQuine Biotherapeutics (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Smith & Nephew (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Genascence (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kolon TissueGene, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Parexel International Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Medipost (South Korea)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mundipharma(Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Osteoarthritis Gene Therapy Sale, by Type, Vectors, End User and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Osteoarthritis Gene Therapy (Value)
      • 7.2.1. Global Osteoarthritis Gene Therapy by: Type (Value)
        • 7.2.1.1. Synovium Injection
        • 7.2.1.2. Cartilage Injection
      • 7.2.2. Global Osteoarthritis Gene Therapy by: Vectors (Value)
        • 7.2.2.1. Non-viral
        • 7.2.2.2. Retrovirus
        • 7.2.2.3. Lentivirus
        • 7.2.2.4. Adenovirus
        • 7.2.2.5. Adeno-associated virus (AAV)
        • 7.2.2.6. HSV
      • 7.2.3. Global Osteoarthritis Gene Therapy by: End User (Value)
        • 7.2.3.1. Hospitals and clinics
        • 7.2.3.2. Orthopedic Centers
        • 7.2.3.3. Assisted living Facilities
        • 7.2.3.4. Nursing Homes
        • 7.2.3.5. Ambulatory Surgical Centers
        • 7.2.3.6. Others
      • 7.2.4. Global Osteoarthritis Gene Therapy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Osteoarthritis Gene Therapy (Price)
      • 7.3.1. Global Osteoarthritis Gene Therapy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Osteoarthritis Gene Therapy: by Type(USD Million)
  • Table 2. Osteoarthritis Gene Therapy Synovium Injection , by Region USD Million (2017-2022)
  • Table 3. Osteoarthritis Gene Therapy Cartilage Injection , by Region USD Million (2017-2022)
  • Table 4. Osteoarthritis Gene Therapy: by Vectors(USD Million)
  • Table 5. Osteoarthritis Gene Therapy Non-viral , by Region USD Million (2017-2022)
  • Table 6. Osteoarthritis Gene Therapy Retrovirus , by Region USD Million (2017-2022)
  • Table 7. Osteoarthritis Gene Therapy Lentivirus , by Region USD Million (2017-2022)
  • Table 8. Osteoarthritis Gene Therapy Adenovirus , by Region USD Million (2017-2022)
  • Table 9. Osteoarthritis Gene Therapy Adeno-associated virus (AAV) , by Region USD Million (2017-2022)
  • Table 10. Osteoarthritis Gene Therapy HSV , by Region USD Million (2017-2022)
  • Table 11. Osteoarthritis Gene Therapy: by End User(USD Million)
  • Table 12. Osteoarthritis Gene Therapy Hospitals and clinics , by Region USD Million (2017-2022)
  • Table 13. Osteoarthritis Gene Therapy Orthopedic Centers , by Region USD Million (2017-2022)
  • Table 14. Osteoarthritis Gene Therapy Assisted living Facilities , by Region USD Million (2017-2022)
  • Table 15. Osteoarthritis Gene Therapy Nursing Homes , by Region USD Million (2017-2022)
  • Table 16. Osteoarthritis Gene Therapy Ambulatory Surgical Centers , by Region USD Million (2017-2022)
  • Table 17. Osteoarthritis Gene Therapy Others , by Region USD Million (2017-2022)
  • Table 18. South America Osteoarthritis Gene Therapy, by Country USD Million (2017-2022)
  • Table 19. South America Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 20. South America Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 21. South America Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 22. Brazil Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 23. Brazil Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 24. Brazil Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 25. Argentina Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 26. Argentina Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 27. Argentina Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 28. Rest of South America Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 29. Rest of South America Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 30. Rest of South America Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 31. Asia Pacific Osteoarthritis Gene Therapy, by Country USD Million (2017-2022)
  • Table 32. Asia Pacific Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 33. Asia Pacific Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 34. Asia Pacific Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 35. China Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 36. China Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 37. China Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 38. Japan Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 39. Japan Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 40. Japan Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 41. India Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 42. India Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 43. India Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 44. South Korea Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 45. South Korea Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 46. South Korea Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 47. Australia Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 48. Australia Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 49. Australia Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 53. Europe Osteoarthritis Gene Therapy, by Country USD Million (2017-2022)
  • Table 54. Europe Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 55. Europe Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 56. Europe Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 57. Germany Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 58. Germany Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 59. Germany Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 60. France Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 61. France Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 62. France Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 63. Italy Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 64. Italy Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 65. Italy Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 66. United Kingdom Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 67. United Kingdom Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 68. United Kingdom Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 69. Netherlands Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 70. Netherlands Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 71. Netherlands Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 72. Rest of Europe Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 73. Rest of Europe Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 74. Rest of Europe Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 75. MEA Osteoarthritis Gene Therapy, by Country USD Million (2017-2022)
  • Table 76. MEA Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 77. MEA Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 78. MEA Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 79. Middle East Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 80. Middle East Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 81. Middle East Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 82. Africa Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 83. Africa Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 84. Africa Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 85. North America Osteoarthritis Gene Therapy, by Country USD Million (2017-2022)
  • Table 86. North America Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 87. North America Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 88. North America Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 89. United States Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 90. United States Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 91. United States Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 92. Canada Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 93. Canada Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 94. Canada Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 95. Mexico Osteoarthritis Gene Therapy, by Type USD Million (2017-2022)
  • Table 96. Mexico Osteoarthritis Gene Therapy, by Vectors USD Million (2017-2022)
  • Table 97. Mexico Osteoarthritis Gene Therapy, by End User USD Million (2017-2022)
  • Table 98. Osteoarthritis Gene Therapy: by Type(USD/Units)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Osteoarthritis Gene Therapy: by Type(USD Million)
  • Table 110. Osteoarthritis Gene Therapy Synovium Injection , by Region USD Million (2023-2028)
  • Table 111. Osteoarthritis Gene Therapy Cartilage Injection , by Region USD Million (2023-2028)
  • Table 112. Osteoarthritis Gene Therapy: by Vectors(USD Million)
  • Table 113. Osteoarthritis Gene Therapy Non-viral , by Region USD Million (2023-2028)
  • Table 114. Osteoarthritis Gene Therapy Retrovirus , by Region USD Million (2023-2028)
  • Table 115. Osteoarthritis Gene Therapy Lentivirus , by Region USD Million (2023-2028)
  • Table 116. Osteoarthritis Gene Therapy Adenovirus , by Region USD Million (2023-2028)
  • Table 117. Osteoarthritis Gene Therapy Adeno-associated virus (AAV) , by Region USD Million (2023-2028)
  • Table 118. Osteoarthritis Gene Therapy HSV , by Region USD Million (2023-2028)
  • Table 119. Osteoarthritis Gene Therapy: by End User(USD Million)
  • Table 120. Osteoarthritis Gene Therapy Hospitals and clinics , by Region USD Million (2023-2028)
  • Table 121. Osteoarthritis Gene Therapy Orthopedic Centers , by Region USD Million (2023-2028)
  • Table 122. Osteoarthritis Gene Therapy Assisted living Facilities , by Region USD Million (2023-2028)
  • Table 123. Osteoarthritis Gene Therapy Nursing Homes , by Region USD Million (2023-2028)
  • Table 124. Osteoarthritis Gene Therapy Ambulatory Surgical Centers , by Region USD Million (2023-2028)
  • Table 125. Osteoarthritis Gene Therapy Others , by Region USD Million (2023-2028)
  • Table 126. South America Osteoarthritis Gene Therapy, by Country USD Million (2023-2028)
  • Table 127. South America Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 128. South America Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 129. South America Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 130. Brazil Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 131. Brazil Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 132. Brazil Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 133. Argentina Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 134. Argentina Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 135. Argentina Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 136. Rest of South America Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 137. Rest of South America Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 138. Rest of South America Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 139. Asia Pacific Osteoarthritis Gene Therapy, by Country USD Million (2023-2028)
  • Table 140. Asia Pacific Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 141. Asia Pacific Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 142. Asia Pacific Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 143. China Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 144. China Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 145. China Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 146. Japan Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 147. Japan Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 148. Japan Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 149. India Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 150. India Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 151. India Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 152. South Korea Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 153. South Korea Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 154. South Korea Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 155. Australia Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 156. Australia Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 157. Australia Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 158. Rest of Asia-Pacific Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 159. Rest of Asia-Pacific Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 160. Rest of Asia-Pacific Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 161. Europe Osteoarthritis Gene Therapy, by Country USD Million (2023-2028)
  • Table 162. Europe Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 163. Europe Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 164. Europe Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 165. Germany Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 166. Germany Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 167. Germany Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 168. France Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 169. France Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 170. France Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 171. Italy Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 172. Italy Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 173. Italy Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 174. United Kingdom Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 175. United Kingdom Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 176. United Kingdom Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 177. Netherlands Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 178. Netherlands Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 179. Netherlands Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 180. Rest of Europe Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 181. Rest of Europe Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 182. Rest of Europe Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 183. MEA Osteoarthritis Gene Therapy, by Country USD Million (2023-2028)
  • Table 184. MEA Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 185. MEA Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 186. MEA Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 187. Middle East Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 188. Middle East Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 189. Middle East Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 190. Africa Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 191. Africa Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 192. Africa Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 193. North America Osteoarthritis Gene Therapy, by Country USD Million (2023-2028)
  • Table 194. North America Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 195. North America Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 196. North America Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 197. United States Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 198. United States Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 199. United States Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 200. Canada Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 201. Canada Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 202. Canada Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 203. Mexico Osteoarthritis Gene Therapy, by Type USD Million (2023-2028)
  • Table 204. Mexico Osteoarthritis Gene Therapy, by Vectors USD Million (2023-2028)
  • Table 205. Mexico Osteoarthritis Gene Therapy, by End User USD Million (2023-2028)
  • Table 206. Osteoarthritis Gene Therapy: by Type(USD/Units)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Osteoarthritis Gene Therapy: by Type USD Million (2017-2022)
  • Figure 5. Global Osteoarthritis Gene Therapy: by Vectors USD Million (2017-2022)
  • Figure 6. Global Osteoarthritis Gene Therapy: by End User USD Million (2017-2022)
  • Figure 7. South America Osteoarthritis Gene Therapy Share (%), by Country
  • Figure 8. Asia Pacific Osteoarthritis Gene Therapy Share (%), by Country
  • Figure 9. Europe Osteoarthritis Gene Therapy Share (%), by Country
  • Figure 10. MEA Osteoarthritis Gene Therapy Share (%), by Country
  • Figure 11. North America Osteoarthritis Gene Therapy Share (%), by Country
  • Figure 12. Global Osteoarthritis Gene Therapy: by Type USD/Units (2017-2022)
  • Figure 13. Global Osteoarthritis Gene Therapy share by Players 2022 (%)
  • Figure 14. Global Osteoarthritis Gene Therapy share by Players (Top 3) 2022(%)
  • Figure 15. Global Osteoarthritis Gene Therapy share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Flexion Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Flexion Therapeutics Inc. (United States) Revenue: by Geography 2022
  • Figure 19. GeneQuine Biotherapeutics (Germany) Revenue, Net Income and Gross profit
  • Figure 20. GeneQuine Biotherapeutics (Germany) Revenue: by Geography 2022
  • Figure 21. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 23. Smith & Nephew (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. Smith & Nephew (United Kingdom) Revenue: by Geography 2022
  • Figure 25. Genascence (United States) Revenue, Net Income and Gross profit
  • Figure 26. Genascence (United States) Revenue: by Geography 2022
  • Figure 27. Kolon TissueGene, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Kolon TissueGene, Inc. (United States) Revenue: by Geography 2022
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2022
  • Figure 31. Parexel International Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 32. Parexel International Corporation (United States) Revenue: by Geography 2022
  • Figure 33. Medipost (South Korea) Revenue, Net Income and Gross profit
  • Figure 34. Medipost (South Korea) Revenue: by Geography 2022
  • Figure 35. Mundipharma(Germany) Revenue, Net Income and Gross profit
  • Figure 36. Mundipharma(Germany) Revenue: by Geography 2022
  • Figure 37. Global Osteoarthritis Gene Therapy: by Type USD Million (2023-2028)
  • Figure 38. Global Osteoarthritis Gene Therapy: by Vectors USD Million (2023-2028)
  • Figure 39. Global Osteoarthritis Gene Therapy: by End User USD Million (2023-2028)
  • Figure 40. South America Osteoarthritis Gene Therapy Share (%), by Country
  • Figure 41. Asia Pacific Osteoarthritis Gene Therapy Share (%), by Country
  • Figure 42. Europe Osteoarthritis Gene Therapy Share (%), by Country
  • Figure 43. MEA Osteoarthritis Gene Therapy Share (%), by Country
  • Figure 44. North America Osteoarthritis Gene Therapy Share (%), by Country
  • Figure 45. Global Osteoarthritis Gene Therapy: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Flexion Therapeutics Inc. (United States)
  • GeneQuine Biotherapeutics (Germany)
  • Novartis AG (Switzerland)
  • Smith & Nephew (United Kingdom)
  • Genascence (United States)
  • Kolon TissueGene, Inc. (United States)
  • Sanofi (France)
  • Parexel International Corporation (United States)
  • Medipost (South Korea)
  • Mundipharma(Germany)
Select User Access Type

Key Highlights of Report


Jun 2023 206 Pages 52 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Osteoarthritis Gene Therapy Market Quantitative research analysis
Global Osteoarthritis Gene Therapy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Osteoarthritis Gene Therapy Market are by type [Synovium Injection and Cartilage Injection], by end use application [].
The Osteoarthritis Gene Therapy Market is gaining popularity and expected to see strong valuation by 2028.
  • Growing Occurrence of Orthopedic Disorders
  • Increase Awareness of Gene Therapy

Know More About Global Osteoarthritis Gene Therapy Market Report?

Have a Query? Click Here

Other Related Reports

Virology Comprehensive Study by Application (Medicine, Agriculture, Nanotechnology, Others), Diagnosis Test (Hepatitis B, Hepatitis C, HIV, Other), Disease (AIDS, Common Cold, Ebola, Genital Herpes, ...
$ 3500
Biotechnology Reagents & Kits Comprehensive Study by Type (Purification Kits, Amplification Kits, Detection Kits, Isolation Kits, Others), Micro-Organisms (Bacteria, Virus, Fungi, Parasites), Technol...
$ 3800
Virology Specimen Collection Comprehensive Study by Application (Diagnostics, Research), End-users (Hospitals & Clinics, Diagnostic Centers, Others), Samples (Blood Samples, Nasopharyngeal Samples, T...
$ 3500
Biotechnology Services Comprehensive Study by Application (Pharmaceutical, Clinical Trial, Healthcare Sectors), Technology (Tissue Engineering and Regeneration, PCR Technology, Nano Biotechnology, Ch...
$ 3500
NGS-Based RNA-Sequencing Comprehensive Study by Type (Sample Preparation, Platforms & Consumables, Services, Data Analysis), Application (Cancer Biomarkers, Cancer Heterogeneity and Drug Resistance, ...
$ 3800
Microarray Analysis Comprehensive Study by Application (DNA Microarray Analysis, RNA Microarray Analysis, Protein Microarray Analysis), Components (Solution, Services), Techniques (Aggregation And No...
$ 3800